Compare
SELLAS Life Sciences Group, Inc. vs Cumberland Pharmaceuticals Inc vs Scienture Holdings, Inc. vs Pyxis Oncology, Inc.
| Latest fiscal year | SELLAS Life Sciences Group, Inc. SLS | Cumberland Pharmaceuticals Inc CPIX | Scienture Holdings, Inc. SCNX | Pyxis Oncology, Inc. PYXS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $44.52M | $431.6K | $13.86M |
| Revenue growth (YoY) | n/a | +17.6% | +215.9% | -14.2% |
| Gross margin | n/a | 85.0% (computed) | 76.8% | 82.8% (computed) |
| Operating margin | n/a | -6.3% | n/m | -609.2% |
| Net margin | n/a | -6.4% | n/m | -574.5% |
| Net income | -$26.86M | -$2.84M | -$41.51M | -$79.62M |
| EPS (Diluted) | -$0.25 | -$0.19 | -$2.70 | -$1.28 |
| Operating cash flow | -$28.39M | $4.93M | -$13.38M | -$63.50M |
| Free cash flow | n/a | $4.83M | n/a | -$63.51M |
| Cash & equivalents | $71.79M | $11.44M | $6.66M | $15.42M |
| Total assets | $78.34M | $76.82M | $84.18M | $91.52M |
| Total liabilities | $7.47M | $52.28M | $14.06M | $38.11M |
| Shareholders' equity | $70.87M | $24.88M | $70.12M | $53.41M |
| Return on year-end equity | -37.9% | -11.4% | -59.2% | -149.1% |
| Shares outstanding | 153.10M | 14.96M | 40.63M | 62.69M |
Revenue, most recent five fiscal years
| Fiscal year | SELLAS Life Sciences Group, Inc. | Cumberland Pharmaceuticals Inc | Scienture Holdings, Inc. | Pyxis Oncology, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $44.52M Ended 2025-12-31 | $431.6K Ended 2025-12-31 | $13.86M Ended 2025-12-31 |
| 1 year earlier | $1.00M Ended 2022-12-31 | $37.87M Ended 2024-12-31 | $136.6K Ended 2024-12-31 | $16.15M Ended 2024-12-31 |
| 2 years earlier | $7.60M Ended 2021-12-31 | $39.55M Ended 2023-12-31 | $1.36M Ended 2023-12-31 | n/a |
| 3 years earlier | $1.90M Ended 2020-12-31 | $42.01M Ended 2022-12-31 | $10.25M Ended 2022-12-31 | n/a |
| 4 years earlier | $0 Ended 2019-12-31 | $35.05M Ended 2021-12-31 | $9.89M Ended 2021-12-31 | n/a |